Status:
COMPLETED
Safety Study of CTS21166 to Treat Alzheimer Disease
Lead Sponsor:
CoMentis
Conditions:
Alzheimer's Disease
Eligibility:
MALE
22+ years
Phase:
PHASE1
Brief Summary
This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers
Eligibility Criteria
Inclusion
- Healthy adult male \> age 21;
- non-smoker (minimum 6 months);
Exclusion
- History or evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease
- History or evidence of intravenous illicit drug use, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C;
- Participation in another clinical trial within 30 days prior to dosing
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00621010
Start Date
June 1 2007
End Date
February 1 2008
Last Update
July 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lifetree Clinical Research
Salt Lake City, Utah, United States, 84106